Eagle Pharmaceuticals (EGRX) Misses Q3 EPS by 27c

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q3 EPS of $0.56, $0.27 worse than the analyst estimate of $0.83. Revenue for the quarter came in at $39.9 million versus the consensus estimate of $46.4 million.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.

You May Also Be Interested In

• Key things to know ahead of SK Hynix’s blockbuster US listing
• Goldman Sachs Upgrades Amorepacific Corp (090430:KS) (AMRPF) to Buy
• Stellantis stock slips as JPMorgan downgrades on delayed payoff from cost cuts